EDARAVONE

Brand name:

• Radicava®

Pharmaceutical company:

Teva Pharma Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Amyotrophic lateral sclerosis (ALS)

PBAC Submission type:

New listing (Category 1)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – November 2023

Related medicines:

--

Submission received for:

November 2023 PBAC meeting

Opportunity for consumer comment:

Open 26/07/2023 and close 20/09/2023 (see PBS Website)

PBAC meeting:

Held on 01/11/2023

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---